Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Celgene Corporation

http://www.celgene.com

Latest From Celgene Corporation

Seres Aims To File C. Diff Microbiome Drug On Single Pivotal Trial

Competing with several other firms to bring the first microbiome-derived therapy to market, Seres says the magnitude of its Phase III efficacy compared to placebo may enough for registrational filing.

Clinical Trials Drug Approval Standards

Roche’s Etrolizumab Failure ‘Removes Big Pipeline Opportunity’

Roche’s etrolizumab missed primary endpoints in its Phase III study program evaluating it as maintenance therapy in moderately to severely active ulcerative colitis, a new therapeutic area for the firm.

Clinical Trials Companies

Stockwatch: Second-Quarter Earnings Highlight The Duracell Bunny PD-1 Inhibitor Race Winner

After the differing second-quarter financial performances of Roche, AstraZeneca and Pfizer’s oncology franchises, the reports by Merck & Co and BMS should have helped define the effects of the pandemic on oncology businesses.

Commercial Companies

Cipla’s Proventil Generic Gnaws At US Market

Cipla’s generic of Merck & Co’s Proventil makes significant inroads in the US, with the Indian company confident that it has both a strong cost position and large capacity to take on competition. Pricing in the segment currently remains ‘respectable’.

Commercial Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • Abraxis BioScience, Inc.
    • AbVitro, Inc.
    • Acetylon Pharmaceuticals, Inc.
    • Avila Therapeutics, Inc.
    • Delinia, Inc.
    • EngMab AG
    • Gloucester Pharmaceuticals, Inc.
    • Impact Biomedicines, Inc.
    • Juno Therapeutics, Inc.
    • Juno Therapeutics GmbH (Stage Cell Therapeutics GmbH)
    • JW Biotechnology (Shanghai) Co., Ltd
    • Pharmion Corporation
    • Quanticel Pharmaceuticals, Inc.
    • Receptos, Inc.
    • RedoxTherapies, Inc.
    • X-BODY, Inc.
UsernamePublicRestriction

Register